ESC 365 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)

ESC Professional Premium Access

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)

Session: Markers of inflammation and outcomes in patients with acute coronary syndromes

Topic: Inflammation

Speaker: Doctor E. Ziogos (Baltimore, US)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Efthymios Ziogos

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

0 follower

4 more presentations in this session

Synergistic effect of Interleukin-1beta and cholesterol efflux capacity on outcomes in acute myocardial infarction patients

Speaker: Doctor C. Materne (Paris, FR)

Analysis of immune infiltration and cuproptosis-related genes in acute myocardial infarction

Speaker: Doctor Y. Xiao (Changsha, CN)

Impact of nutritional status and systemic immune-inflammation index on mortality in patients with acute myocardial infarction

Speaker: Doctor H. Kwak (Daegu, KR)

Inflammatory biomarkers and long-term outcome in young stable patients 3 months after a first myocardial infarction

Speaker: Doctor S. Cederstrom (Stockholm, SE)

Access the full session

Markers of inflammation and outcomes in patients with acute coronary syndromes

Speakers: Doctor E. Ziogos, Doctor C. Materne, Doctor Y. Xiao, Doctor H. Kwak, Doctor S. Cederstrom

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources